According to a recent LinkedIn post from Aignostics, the company is promoting its Research Access Program, which offers academic researchers free use of its Atlas H&E-TME spatial tumor microenvironment analysis tool. The post describes benefits including full processing of H&E slides, multi-level spatial readouts, polygon overlays in a pathology viewer, and dedicated support at no cost to apply or participate.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Aignostics is pursuing broader academic adoption of its AI-driven pathology technology, potentially strengthening its data assets, validation base, and relationships with key opinion leaders. For investors, such a program could support long-term commercial prospects by accelerating evidence generation and showcasing the platform’s capabilities to future clinical and biopharma partners, though near-term direct revenue impact appears limited given the free-access structure.